Revenue and earnings declined as key projects entered clinical phases, but Corline is preparing for a US launch with Kardium and expanding into regenerative medicine. Cash position and financing are being closely managed.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.